思路迪

“成为肿瘤精准医疗领域的创新型领导者”

制药/生物工程 / 500-1000人 / 南宁、福州、海口等地

新药研发

成员介绍

  • David Liu/CMO

    Engaged in research and development of oncology drugs for nearly 20 years with extensive training in both basic science and clinical medicine; Experienced in global clinical development of biologic and small molecules in both solid and blood malignancies. Former Executive Medical Director at Celgene USA; Former Group Medical Director at BMS

  • Jeffery Lin/Director,Preclinical Drug R&D

    Leads 3DMed bio-marker discovery Former Senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia Ph.D in Biochemistry and Molecular Bioloy from Chinese Academy of Sciences, Post-Doc from the Chinese Academy of Science Institute of Health

  • Amanda Fu/VP of Clinical Operation

    Over 15 years` industry experience in clinical operation across AsiaPac. North America, South America, Europe and Australia. Former General Manager of Gleneagles CRC(China)Pte.Ltd. in China. Former Global Clinical Operation Team Lead at GE Health in US. Former Global Project Lead at Syneos Health in US. Former Clinical operation and Development Director at Pharmacyclics in US.

  • Walt Cao/Head,Clinical Pharmacology&Pharmacometri

    16 years work experience in new drug design, translational sciences, clinical research and development. Former US FDA senior clinical pharmacology reviewer and biosimilar lead for oncology drug. Former Senior Scientist in Boehringer Ingelheim and Abbott/AbbVie

  • Haolan Lu/Senior Biostatistics Director

    Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology pioneering drugs: Opdivo and Yervoy. Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC PH.D. in Biostatistics from University of Minnesota.

我们的团队

全球首个抗PD-L1单域抗体新药KN035连续推进在中、美、日三地的药物临床试验

新药研发团队在招职位

思路迪的其他团队